aTyr Pharma (STU:471A) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:471A aTyr Pharma Inc STU:471A
16 GF Score
Price €0.38
GF Value €0.45
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is aTyr Pharma SpecialCharges?

Special Charges only applies to banks.

STU:471A
16GF Score
aTyr Pharma Inc STU:471A
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is aTyr Pharma (STU:471A) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be undervalued. The current stock price of €0.38 is trading 16.4% below its estimated GF Value™ of €0.45. GuruFocus considers aTyr Pharma to be Modestly Undervalued.

Key valuation signals for STU:471A:

  • SpecialCharges:
  • GF Value™: €0.45 vs. price of €0.38 (16.4% below fair value)
  • GF Score™: 16/100 with 3 warning signs

No single metric tells the full story. See the STU:471A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


aTyr Pharma Business Description

Other Exchanges ATYR:USA
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
16GF Score

Get the complete analysis for STU:471A

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price
€0.45
GF Value